Robinson Pharma Inc., (RPI; Santa Ana, CA) announced its completion of a surveillance audit for cGMP compliant manufacture of dietary supplements on January 9. The audit was performed by STR (Enfield, CT), a third party testing and auditing firm with a focus on quality systems and analysis.
Robinson Pharma Inc., (RPI; Santa Ana, CA) announced its completion of a surveillance audit for cGMP compliant manufacture of dietary supplements on January 9.
The audit was performed by STR (Enfield, CT), a third party testing and auditing firm with a focus on quality systems and analysis.
According to RPI, the company has undergone significant investments in manufacturing systems that feature a “hands free – constant monitoring” approach to all aspects of manufacturing process. These include investing resources in designing systems that support effective ingredient receipt and testing, pharmacy and pre-production processing, manufacturing, post production testing, and packaging.
“Last year we committed to the RQP. This year we have demonstrated that we can maintain a high level of quality simultaneous to expanding our production capacity and speeding our pace of delivery to our customers,” said RPI president and founder, Tuong Nguyen.
“Partnering with STR, along with other key strategic initiatives, has facilitated the transformation of RPI from a contract manufacturer to a…private label supplier of some of the leading marketers of dietary supplements in the United States and other international markets” said Kenn Israel, vice president of marketing.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.